Early National Dissemination of Abiraterone and Enzalutamide for Advanced Prostate Cancer in Medicare Part D
Caram M, Borza T, Min H, Griggs J, Miller D, Hollenbeck B, Mukherjee B, Skolarus T. Early National Dissemination of Abiraterone and Enzalutamide for Advanced Prostate Cancer in Medicare Part D. JCO Oncology Practice 2017, 13: jop.2016.020206. PMID: 28628393, PMCID: PMC5555032, DOI: 10.1200/jop.2016.020206.Peer-Reviewed Original ResearchConceptsMetastatic castration-resistant prostate cancerHospital referral regionsProstate cancerMetastatic castration-resistant prostate cancer treatmentCastration-resistant prostate cancerProvider specialtyAdvanced prostate cancerMedicare Part DProstate cancer incidenceFood and Drug AdministrationMinority of providersYears of ageEnzalutamide prescriptionsMultilevel regression modelsMedicare Part D dataPart DEnzalutamideAbirateroneMedical oncologistsMedical oncologyEarly disseminationTreated menPart D dataCancer incidenceWorkforce densityEarly national dissemination of abiraterone and enzalutamide for advanced prostate cancer in Medicare Part D.
Caram M, Borza T, Min H, Griggs J, Miller D, Hollenbeck B, Mukherjee B, Skolarus T. Early national dissemination of abiraterone and enzalutamide for advanced prostate cancer in Medicare Part D. Journal Of Clinical Oncology 2017, 35: 35-35. DOI: 10.1200/jco.2017.35.8_suppl.35.Peer-Reviewed Original ResearchAdvanced prostate cancerHospital referral regionsProstate cancerProvider specialtyAdvanced prostate cancer treatmentProstate cancer incidenceProstate cancer treatmentMedicare Part DEnzalutamide prescriptionsFood & Drug AdministrationMedicare Part D dataEnzalutamideMinority of providersAbirateroneMedical oncologistsOral medicationsMedical oncologyEarly disseminationTreated menPart D dataCancer incidenceDrug AdministrationCancer treatmentMultilevel regression modelsPart D